Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zlatibor Velickovic is active.

Publication


Featured researches published by Zlatibor Velickovic.


Immunogenetics | 2006

Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations

Marija Velickovic; Zlatibor Velickovic; H. Dunckley

Killer immunoglobulin-like receptors (KIRs) regulate the activity of NK and T cells through interaction with specific HLA class I molecules on target cells. To date, 16 KIR genes and pseudogenes have been identified. Diversity in KIR gene content and KIR allelic and haplotype polymorphism has been observed between different ethnic groups. Here, we present data on the KIR gene distribution in Pacific Islands populations. Sixteen KIR genes were observed in Pacific Islands populations from the Cook Islands, Samoa, Tokelau, and Tonga. The majority of KIR genes were present at similar frequencies between the four populations with KIR2DL4, KIR3DL2, and KIR3DP1 genes observed in all individuals. Commonly observed KIR genes in Pacific Islands populations (pooled frequencies) were KIR2DL1 (0.77), KIR2DL3 (0.77), KIR3DL1 (0.65), KIR3DL3 (0.93), KIR2DS4/1D (0.78), and KIR2DP1 (0.82), compared to the less-frequently observed KIR2DL2 (0.27), KIR2DL5 (0.30), KIR2DS1 (0.19), KIR2DS2 (0.27), KIR2DS3 (0.16), KIR2DS5 (0.17), and KIR3DS1 (0.18) genes. Differences in KIR gene frequency distributions were observed between the Pacific Islands populations and when compared to other populations. Sixty-nine different genotypes were identified, with five genotypes accounting for more then 50% of all genotypes observed. The number of genotypes observed in each population was similar in the Cook Islands, Samoan, and Tokelauan populations (19, 18, and 19, respectively), but 26 different genotypes were observed in Tongans. The putative haplotype A was predominantly observed over haplotype B in all Pacific Islands populations. Significant linkage disequilibrium was observed for a number of KIR gene pairs.


Tissue Antigens | 2009

Diversity of killer cell immunoglobulin-like receptor genes in Indonesian populations of Java, Kalimantan, Timor and Irian Jaya

Marija Velickovic; Zlatibor Velickovic; R. Panigoro; H. Dunckley

Killer cell immunoglobulin-like receptors (KIRs) regulate the activity of natural killer and T cells through interactions with specific human leucocyte antigen class I molecules on target cells. Population studies performed over the last several years have established that KIR gene frequencies (GFs) and genotype content vary considerably among different ethnic groups, indicating the extent of KIR diversity, some of which have also shown the effect of the presence or absence of specific KIR genes in human disease. We have determined the frequencies of 16 KIR genes and pseudogenes and genotypes in 193 Indonesian individuals from Java, East Timor, Irian Jaya (western half of the island of New Guinea) and Kalimantan provinces of Indonesian Borneo. All 16 KIR genes were observed in all four populations. Variation in GFs between populations was observed, except for KIR2DL4, KIR3DL2, KIR3DL3, KIR2DP1 and KIR3DP1 genes, which were present in every individual tested. When comparing KIR GFs between populations, both principal component analysis and a phylogenetic tree showed close clustering of the Kalimantan and Javanese populations, while Irianese populations were clearly separated from the other three populations. Our results indicate a high level of KIR polymorphism in Indonesian populations that probably reflects the large geographical spread of the Indonesian archipelago and the complex evolutionary history and population migration in this region.


Tissue Antigens | 2012

Using HLA loci to inform ancestry and health in Polynesian and Maori populations

H. A. Edinur; P. P. J. Dunn; L. Hammond; C. Selwyn; Zlatibor Velickovic; Rodney Arthur Lea; Geoffrey K. Chambers

Human leukocyte antigens (HLA) are important genetic markers of tissue identity and accurately reflect ancestral history. The work reported in this paper provides a detailed description of HLA polymorphism in Polynesian and Maori individuals in relation to other populations. Our study concerns HLA classes I and II antigens in Polynesian (N = 36) and Maori (N = 114) subjects genotyped at two digit resolution by New Zealand Blood Service Laboratory in Auckland using polymerase chain reaction-sequence specific oligonucleotide and PCR-SSP technologies. We have also compared our data with those from other Austronesian-speaking Mongoloid and Papuan-speaking Australoid populations in order to test previously published account of the origin of Proto-Polynesians via gender-biassed gene flow between these two ancestral populations. We use principal coordinate analysis for this purpose, arguing this approach to be superior to tree-based methods, because of factors associated with population history and admixture. Our data are in general agreement with earlier work and reflect received wisdom on the dual origin of Proto-Polynesians. They also show the way in which the genetic make-up of Polynesian and Maori subjects is changing due to intermarriage with Europeans.


Tissue Antigens | 2010

Diversity of killer cell immunoglobulin‐like receptor genes in Indonesian populations of Sumatra, Sulawesi and Moluccas Islands

Marija Velickovic; Zlatibor Velickovic; R. Panigoro; H. Dunckley

Killer immunoglobulin-like receptors (KIRs) regulate the activity of natural killer and T cells through interaction with specific human leukocyte antigen (HLA) molecules on target cells. Like HLA class I genes that are characterised by extreme allelic polymorphism, KIR genes are diverse and vary in both gene content and allelic polymorphism. Population studies conducted over the last several years have showed that KIR gene frequencies (GF) and genotype content vary among different ethnic groups, indicating the extent of KIR diversity. Some studies have also shown the effect of the presence or absence of specific KIR genes in human disease. We have recently reported the distribution of KIR genes in populations from Java (Central Javanese and the Sundanese of West Java), East Timor (Timorese), Kalimantan provinces of Indonesian Borneo (Dayaks) and Irian Jaya (Western half of the island of New Guinea; Melanese). We here extend analysis of the KIR genes in populations from North Sulawesi (Minahasans), West Sumatra (Minangs) and Moluccas Islands. All 16 KIR genes were observed in all three populations. Variation in GF between populations was observed, except for the KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1 genes, which were present in every individual tested. When comparing KIR GF between populations, both principal component analysis and phylogenetic tree analyses showed a close relationship between Minahasan and Moluccan populations that are clustered with Timorese in the same clade. The Minang tribe lies between the Javanese/Kalimantan and the Timorese/Minahasan/Moluccan clades, whereas Irianese show the greatest genetic distances from other Indonesian populations. The results correspond well with the history of migration in Indonesia and will contribute to the understanding of the genetic as well as the geographic history of the region.


Pathology | 2014

Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.

Craig Wright; Zlatibor Velickovic; Ross D. Brown; Stephen Larsen; Janet L. Macpherson; John Gibson; John E.J. Rasko

Summary In Australia, manufacture of blood, tissues and biologicals must comply with the federal laws and meet the requirements of the Therapeutic Goods Administration (TGA) Manufacturing Principles as outlined in the current Code of Good Manufacturing Practice (cGMP). The Therapeutic Goods Order (TGO) No. 88 was announced concurrently with the new cGMP, as a new standard for therapeutic goods. This order constitutes a minimum standard for human blood, tissues and cellular therapeutic goods aimed at minimising the risk of infectious disease transmission. The order sets out specific requirements relating to donor selection, donor testing and minimisation of infectious disease transmission from collection and manufacture of these products. The Therapeutic Goods Manufacturing Principles Determination No. 1 of 2013 references the human blood and blood components, human tissues and human cellular therapy products 2013 (2013 cGMP). The name change for the 2013 cGMP has allowed a broadening of the scope of products to include human cellular therapy products. It is difficult to directly compare versions of the code as deletion of some clauses has not changed the requirements to be met, as they are found elsewhere amongst the various guidelines provided. Many sections that were specific for blood and blood components are now less prescriptive and apply to a wider range of cellular therapies, but the general overall intent remains the same. Use of ‘should’ throughout the document instead of ‘must’ allows flexibility for alternative processes, but these systems will still require justification by relevant logical argument and validation data to be acceptable to TGA. The cGMP has seemingly evolved so that specific issues identified at audit over the last decade have now been formalised in the new version. There is a notable risk management approach applied to most areas that refer to process justification and decision making. These requirements commenced on 31 May 2013 and a 12 month transition period applies for implementation by manufacturers. The cGMP and TGO update follows the implementation of the TGA regulatory biologicals framework for cell and tissue based therapies announced in 2011. One implication for licenced TGA facilities is that they must implement the 2013 cGMP, TGO 88 and other relevant TGOs together, as they are intricately linked. This review is intended to assist manufacturers by comparing the 2000 version of the cGMP, to the new 2013 cGMP, noting that the new Code extends to include human cellular therapy products.


Virologica Sinica | 2014

Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus

Fang Fang Yuan; Zlatibor Velickovic; Lesley J. Ashton; Wayne B. Dyer; Andrew F. Geczy; H. Dunckley; Garry W. Lynch; John S. Sullivan

Dear Editor,Severe Acute Respiratory Syndrome(SARS)has beendescribed as the first pandemic of the 21st century andbetween November 2002 and July 2003,over 8000 peo-ple were infected with the SARS-associated coronavirus(SARS-CoV).Polymorphisms in the human leukocyteantigen(HLA)system have been shown to influencesusceptibility to SARS-CoV but here we were unable to


Human Immunology | 2013

HLA and MICA polymorphism in Polynesians and New Zealand Maori: implications for ancestry and health.

H. A. Edinur; Paul P.J. Dunn; L. Hammond; Caroline Selwyn; P. Brescia; Medhat Askar; P. Reville; Zlatibor Velickovic; Rodney Arthur Lea; Geoffrey K. Chambers


Tissue Antigens | 2004

Identification of two novel HLA class II alleles, DQB1*030503 and DRB1*0447

Zlatibor Velickovic; Hogbin Jp; Truong J; S. Jaafar; H. Dunckley


Tissue Antigens | 2004

A new HLA-B allele, B*1565, identified in three unrelated samples

H. Dunckley; R. Dodd; W.D. Greville; J. Hersee; T. Le; A. Taverniti; R. Wallace; J. Strickland; Hogbin Jp; Truong J; Zlatibor Velickovic


Tissue Antigens | 2004

Identification of three novel HLA class I alleles: HLA-B*3928, HLA-B*400104 and HLA-B*4437

Zlatibor Velickovic; R. Dodd; Marija Velickovic; J. Hersee; T. Le; A. Taverniti; R. Wallace; H. Dunckley

Collaboration


Dive into the Zlatibor Velickovic's collaboration.

Top Co-Authors

Avatar

H. Dunckley

Australian Red Cross Blood Service

View shared research outputs
Top Co-Authors

Avatar

Marija Velickovic

Australian Red Cross Blood Service

View shared research outputs
Top Co-Authors

Avatar

Hogbin Jp

Australian Red Cross Blood Service

View shared research outputs
Top Co-Authors

Avatar

A. Taverniti

Australian Red Cross Blood Service

View shared research outputs
Top Co-Authors

Avatar

Craig Wright

Royal Prince Alfred Hospital

View shared research outputs
Top Co-Authors

Avatar

J. Hersee

Australian Red Cross Blood Service

View shared research outputs
Top Co-Authors

Avatar

Janet L. Macpherson

Royal Prince Alfred Hospital

View shared research outputs
Top Co-Authors

Avatar

John E.J. Rasko

Royal Prince Alfred Hospital

View shared research outputs
Top Co-Authors

Avatar

R. Dodd

Australian Red Cross Blood Service

View shared research outputs
Top Co-Authors

Avatar

R. Wallace

Australian Red Cross Blood Service

View shared research outputs
Researchain Logo
Decentralizing Knowledge